Maravai LifeSciences (MRVI) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed UroGen Pharma (URGN) over the past year, gaining 116.5% versus a gain of 113.4%. Over five years, URGN leads with a +117.3% price change compared with -80.6% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.76 billion vs $1.82 billion), about 1.5 times the size, while UroGen Pharma is growing revenue faster (+21.4% vs -28.3%).
Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | URGN |
|---|---|---|
| Share price | $7.45 | $37.31 |
| Market cap | $2.76B | $1.82B |
| 1-day change | +3.26% | +0.88% |
| YTD return | +121.85% | +57.90% |
| 1-year return | +116.52% | +113.39% |
| 5-year return | -80.56% | +117.27% |
| Forward P/E | — | 13.35 |
| EPS (TTM) | $-0.53 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $109.79M |
| Revenue growth (YoY) | -28.34% | +21.45% |
| Net income (latest FY) | $-130.77M | $-153.49M |
| Gross margin | 18.30% | 88.66% |
| Operating margin | -115.89% | -113.73% |
| Net margin | -70.41% | -139.81% |
| 52-week high | $9.42 | $50.81 |
| 52-week low | $2.55 | $15.86 |
| Distance from 52-week high | -20.97% | -26.58% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.17% | +60.84% |
| Average volume | 3.36M | 849.01K |
| Shares outstanding | 148.99M | 48.88M |
| Employees | 415 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- UroGen Pharma grew revenue faster in its latest fiscal year (+21.45% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
MRVI vs URGN FAQ
Which is bigger, Maravai LifeSciences or UroGen Pharma?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.76B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, MRVI or URGN?
MRVI returned +116.52% over the past 12 months, compared with +113.39% for URGN (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.